Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies: Guidance for Industry and Investigators
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 20, 2012
April 24, 2020
9528f5d8-c247-4fdc-8dc2-a32ec6d6afad
Related Documents
S6(R1) Addendum: Preclinical Safety Evaluation of Biotechnology: Guidance for Industry
Guidance DocumentDecember 17, 2009Center for Drug Evaluation and Research
Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators
Guidance DocumentDecember 20, 2012Center for Drug Evaluation and Research
Q11 Development and Manufacture of Drug Substances
Guidance DocumentNovember 20, 2012Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox